Students Validate Optimal Caffeine Dosage for Newborns With Heart Disease

Researchers and students from Montana State University and Duke University have validated a study to determine the optimal caffeine dosage for newborns diagnosed with congenital heart disease. The findings, which provide a foundation for tailoring dosages to the specific needs of these infants, have implications for medical treatment in hospitals across the United States.

The research was published on February 9, 2026, in the Journal of Pediatric Pharmacology and Therapeutics. The study focused on the pharmacokinetic model evaluation of caffeine in critically ill neonates with heart disease, utilizing data collected from a pragmatic platform trial.

Preventing Acute Kidney Injury

The administration of caffeine in neonates is used to improve blood flow. According to reports from Montana State University, this improvement in blood flow can reduce the likelihood of newborns developing acute kidney injury, a condition that can potentially lead to chronic kidney disease.

Because newborns with congenital heart disease are particularly vulnerable, establishing a precise and effective dosage is critical for improving patient outcomes and ensuring the safety of the treatment.

Research Methodology and Findings

The study was led by Dr. Danny Benjamin, a principal investigator at Duke University STAR and an affiliate professor in the Department of Microbiology and Cell Biology at Montana State University. The research team utilized mathematical modeling and analyzed leftover blood samples from neonate patients to examine how caffeine is metabolized.

Through this analysis, the team examined the differences in caffeine metabolism specifically within neonates suffering from congenital heart disease. Dosing simulations conducted during the study revealed that these neonates experienced lower caffeine exposures compared to other groups.

By meticulously analyzing data and conducting rigorous experiments, the researchers established a solid foundation for determining the most effective caffeine dosage tailored to the requirements of these vulnerable infants.

Collaborative Academic Effort

The project represented a significant collaboration between several institutions, including the Duke Clinical Research Institute, the University of Washington School of Medicine, and Montana State University.

The published paper lists several contributors from these institutions, including Courtney Hallock, Annalisa Hawk, Calla Castro, Jessminda DiCello, and Andrea L. Storer. Other contributors included Rachel Sielaty, Henry P. Foote, and several other researchers from the Duke Clinical Research Institute and the Department of Pediatrics.

Clinical Implications and Implementation

The external validation of this research is a key step toward widespread clinical application. While the initial study was conducted at Duke, this validation opens the door for the dosing strategies to be implemented in hospitals nationwide.

Dr. Benjamin noted that the validation not only validates the initial study but also paves the way for improved treatment strategies and outcomes for newborns with congenital heart disease.

The ability to implement these findings on a national scale means a broader spectrum of patients can benefit from optimized caffeine dosing, moving beyond the initial patient group studied at Duke University.